LIfT BioSciences
LIfT BioSciences develops Immunomodulatory Alpha Neutrophils (IMANs), which are off-the-shelf neutrophil-lineage cell therapies designed to treat solid tumours. These therapies aim to directly kill tumour cells and activate the patient's innate immune system. The company is preparing for first-in-human Phase 1 clinical studies targeting patients with advanced cervical and head and neck cancers.
Visit websiteLondon, United Kingdom
Biotech
Healthcare
Oncology
Immunotherapy
Funding summary
- Total raised
- €12.0M
- Funding rounds
- 1
Investors in LIfT BioSciences
Investors on record for LIfT BioSciences. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like LIfT BioSciences?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors